Join the Zepbound group to help and get support from people like you.
Zepbound News (Page 5)
Can Elderberry Juice Help You Lose Weight?
FRIDAY, Jan. 10, 2025 – Ozempic? Wegovy? Zepbound? How about elderberry juice? Elderberry juice might help people lose weight and improve their blood sugar control, a new small-scale study says....
Some GLP-1s Achieve More Weight Loss Than Others: Study
WEDNESDAY, Jan. 8, 2025 – Three GLP-1 drugs are best at helping obese and overweight people drop weight, including one that hasn’t yet been approved for that purpose. A new evidence review published ...
GLP-1 RAs Efficacious for Weight Loss in Overweight, Obesity Without Diabetes
TUESDAY, Jan. 7, 2025 – For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious for weight loss, according to a review published...
How do GLP-1s Boost Weight Loss, Heart Health?
THURSDAY, Jan. 2, 2024 – Weight loss tops many folks’ list of New Years resolutions, and lots of people are turning to cutting-edge weight-loss drugs like Ozempic to help them drop excess pounds. T...
Weight-Loss Drugs, Wily Viruses, Abortion Pill Under Attack: The Top Health Stories of 2024
MONDAY, Dec. 30, 2024 – It was a year in health news that will be hard to forget. As blockbuster weight-loss drugs known as GLP-1s made a sizable dent in the obesity epidemic, study after study...
FDA Approves Zepbound (tirzepatide) as the First and Only Prescription Medicine for Moderate-to-Severe Obstructive Sleep Apnea in Adults with Obesity
INDIANAPOLIS, Dec. 20, 2024 /PRNewswire/ – Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound (tirzepatide) as the first and only...
FDA Approves Zepbound for Sleep Apnea in Patients With Obesity
MONDAY, Dec. 23, 2024 – The U.S. Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA). In a news...
GLP-1 Receptor Agonist Zepbound Approved as First Drug for Obstructive Sleep Apnea in Individuals with Obesity
MONDAY, Dec. 23, 2024 – The U.S. Food and Drug Administration (FDA) has approved the first prescription medication specifically for treating obstructive sleep apnea (OSA): the weight-loss drug...
FDA Says Shortage of GLP-1 Tirzepatide (Mounjaro, Zepbound) Is Over
THURSDAY, Dec. 19, 2024 – The U.S. Food and Drug Administration re-issued a decision first made by the agency in October that a shortage of the diabetes/weight-loss medication tirzepatide is over....
U.S. Adult Obesity Rate Fell in 2023, as Use of GLP-1 Meds Rose
FRIDAY, Dec. 13, 2024 – The U.S. obesity rate declined for the first time in a decade last year, coinciding with the rise of GLP-1 weight-loss meds, a new study finds. Data on almost 17 million...
Weight Loss Brings Americans Big Health Care Savings
THURSDAY, Dec. 5, 2024 – The advent of GLP-1 weight-loss medications such as Wegovy and Zepbound has spurred debate as to whether the drugs' cost should be covered by Medicare, Medicaid and private...
Zepbound Bests Wegovy for Weight Loss in New Trial
WEDNESDAY, Dec. 4, 2024 – Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly. "Given the increased...
American Heart Association, Nov. 16-18
The annual meeting of the American Heart Association was held this year from Nov. 16 to 18 in Chicago, drawing attendees from around the world, including cardiovascular specialists, surgeons, and n...
Biden Seeks Coverage for GLP-1 RA Medications by Medicare, Medicaid
TUESDAY, Nov. 26, 2024 – The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist (GLP-1 RA) obesity medications like semaglutide (Wegovy)...
Zepbound Slashes Diabetes Risk in Obese Users
WEDNESDAY, Nov. 27, 2024 – The cutting-edge weight-loss drug Zepbound can protect obese people from developing type 2 diabetes, a new clinical trial has found. Zepbound reduced the risk of diabetes...
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Obstructive Sleep Apnea/Hypopnea Syndrome